Please login to the form below

Zontivity

This page shows the latest Zontivity news and features for those working in and with pharma, biotech and healthcare.

FDA reviewer backs approval of TMC's cangrelor

Additional competition in the category will also come from Merck &Co's first-in-class protease-activated receptor-1 (PAR-1) antagonist Zontivity (vorapaxar) - which was cleared for marketing in the

Latest news

R&D productivity takes off

Other first-in-class agents include: Merck &Co's PAR-1 antagonist Zontivity (vorapaxar), a novel antiplatelet agent; AstraZeneca's PARP inhibitor Lynparza (olaparib) for cancer; Otsuka's Deltyba (delamanid), a
Orphan drugs in latest CHMP recommendations

s Zontivity (vorapaxar), which was recommended for the reduction of atherothrombotic events.
Merck's first-in-class Zontivity cleared in US

After a long haul, Merck &Co's Zontivity has become the first drug in the new protease-activated receptor-1 (PAR-1) antagonist class to be approved for marketing in the ... Merck plans to launch Zontivity in the US in the coming weeks, while the PAR-1
FDA panel backs Merck's vorapaxar

Vorapaxar - which Merck plans to sell under the brand name Zontivity - is an orally-active protease-activated receptor 1 (PAR-1) inhibitor that targets thrombin-induced platelet activation. ... If the FDA follows the panel's advice - which it generally

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

Deal Watch September 2016

Merck &Co has sold the US and Canadian rights for its Zontivity, or vorapaxar, to Aralez Pharmaceuticals in an asset purchase agreement worth $25m. ... Zontivity is a protease-activated receptor-1 antagonist indicated for use in combination with daily

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

OPEN Health attend EB World Congress—building on momentum and strength in numbers for epidermolysis bullosa: Ben Speller shares his thoughts on the value of disease specific congresses...
OPEN Health use PR to support clinical trial recruitment: International Clinical Trials Day finds clinical research in the spotlight like never before, with any news coming from the many studies into potential vaccines and treatments for SARS-CoV-2...
Covid-19: what could it mean for the diabetic population?: Steve How and Oli Hudson, of Wilmington Healthcare, assess the scale of the diabetes crisis and how coronavirus might impact on it...